Metastatic
-
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Phase 2 · randomised · 302 people · 109 sites in 22 countries · Running, not taking new patients
-
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Phase 2 · 225 people · 53 sites in 11 countries · Recruiting now
-
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Phase 3 · randomised · 550 people · 2 sites in China · Opening soon
-
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Phase 3 · randomised · 901 people · 133 sites in 16 countries · Running, not taking new patients
-
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Phase 3 · randomised · 461 people · 419 sites in 32 countries · Running, not taking new patients
-
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Phase 3 · randomised · 408 people · 62 sites in United States · Recruiting now
-
Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
Phase 3 · randomised · 244 people · 4 sites in France · Recruiting now
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Phase 2 · randomised · 390 people · 59 sites in 14 countries · Recruiting now
-
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
Phase 3 · randomised · 960 people · 1 site in Puerto Rico · Recruiting now
-
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Phase 3 · randomised · 800 people · 285 sites in 17 countries · Recruiting now